Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib with Bendamustine and Rituximab in Newly Diagnosed MCL
NCT06136351Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by Ruijin Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06136351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136351.